tert-butyl (2-(4-fluorophenoxy)ethyl)carbamate | 263409-78-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: tert-butyl (2-(4-fluorophenoxy)ethyl)carbamate
• 英文别名: (2-(4-fluorophenoxy)-ethyl)-carbamic acid tert-butyl ester；t-butyl 2-(4-fluorophenoxy)ethylcarbamate；tert-butyl N-[2-(4-fluorophenoxy)ethyl]carbamate
• CAS: 263409-78-5
• 化学式: C₁₃H₁₈FNO₃
• mdl: MFCD24393200
• 分子量: 255.289
• InChiKey: JIHHLNQLKIXGKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (2-(4-fluorophenoxy)ethyl)carbamate 在 三氟乙酸 作用下， 反应 0.5h， 生成 2-(4-氟苯氧基)乙胺
  参考文献：
  名称：

  [EN] MUSCARINIC AGONISTS
  [FR] AGONISTES MUSCARINIQUES

  摘要：

  本发明涉及以下式（I）的化合物，它们是M-1肌胆碱受体的激动剂。

  公开号：

  WO2004094363A1
• 作为产物：
  描述：

  2-(4-氟苯氧基)乙腈 在 platinum(IV) oxide 偶氮二甲酸二异丙酯 、 氢气 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 生成 tert-butyl (2-(4-fluorophenoxy)ethyl)carbamate
  参考文献：
  名称：

  Development of a scalable synthesis of a nonbasic inhibitor of the serine protease tryptase

  摘要：

  A chromatography-free process for the synthesis of a bis(benzimidazole)difluoromethane inhibitor of the serine protease tryptase is described. This synthesis features the introduction of the cm-difluoro moiety using the electrophilic fluorinating reagent N-fluoro-bis(phenylsulfonimide) as well as the stepwise introduction of both benzimidazole rings. A protocol for the destruction of reactive, process-related substances produced in the synthesis is also presented. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2006.04.149

文献信息

• [EN] HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES<br/>[FR] DERIVES D'HYDROXY-TETRAHYDRO-NAPHTALENYLUREE
  申请人：BAYER HEALTHCARE AG

  公开号：WO2004072020A1

  公开（公告）日：2004-08-26

  This invention relates to hydroxy-tetrahydro-naphthalenylurea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The hydroxy-tetrahydro-naphthalenylurea derivatives of the present invention have an excellent activity as VRl antagonist and are useful for the prophylaxis and treatment of diseases associated with VRl activity, in particular for the treatment of urinary incontinence, urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.

  这项发明涉及羟基-四氢-萘尿素衍生物及其盐，可作为药物配方的有效成分。本发明的羟基-四氢-萘尿素衍生物具有优异的VRl拮抗活性，适用于预防和治疗与VRl活性相关的疾病，特别是用于治疗尿失禁、急迫性尿失禁、过度活跃膀胱、慢性疼痛、神经痛、术后疼痛、类风湿性关节炎疼痛、神经痛、神经病、疼痛、神经损伤、缺血、神经退行性疾病、中风、炎症性疾病、哮喘和COPD的治疗。
• Muscarinic agonists
  申请人：Allen Rebecca Jennifer

  公开号：US20060178438A1

  公开（公告）日：2006-08-10

  The present invention relates to compounds of Formula (I): which are agonists of the M-1 muscarinic receptor.

  本发明涉及式（I）的化合物，该化合物是M-1肌动蛋白受体的激动剂。
• Ether derivative
  申请人：Okuzumi Tatsuya

  公开号：US20060270693A1

  公开（公告）日：2006-11-30

  The present invention relates to an ether derivative represented by the formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description, and an ether derivative represented by the formula (III), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description; a pharmaceutical composition containing the ether derivative; and a package containing the pharmaceutical composition and a description of use thereof. A pharmaceutical composition of the present invention, which contains this compound of the present invention has a superior anti-inflammatory and analgesic activity and is useful as various pharmaceutical agents such as an anti-inflammatory agent, an analgesic, a therapeutic agent for inflammatory bowel disease, a therapeutic agent for pollakiuria and/or incontinentia, a therapeutic agent for asthma and the like.

  本发明涉及一种以式(I)表示的醚衍生物，其药学上可接受的盐、水合物或溶剂化物，其中每个符号如描述中所定义的，并且一种以式(III)表示的醚衍生物，其药学上可接受的盐、水合物或溶剂化物，其中每个符号如描述中所定义的；一种含有该醚衍生物的制药组合物；以及一个包含该制药组合物及其使用说明的包装。本发明的制药组合物，包含该化合物具有优异的抗炎和镇痛活性，并且可用作各种药物剂型，如抗炎剂、镇痛剂、治疗炎症性肠病的治疗剂、治疗排尿过频和/或失禁的治疗剂、治疗哮喘等。
• Hydroxy-tetrahydro-naphthalenylurea derivatives
  申请人：Yura Takeshi

  公开号：US20070027187A1

  公开（公告）日：2007-02-01

  This invention relates to hydroxy-tetrahydro-naphthalenylurea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The hydroxy-tetrahydro-naphthalenylurea derivatives of the present invention have an excellent activity as VR1 antagonist and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.

  本发明涉及羟基四氢萘基脲衍生物及其盐，它们是制备药物的有效成分。本发明的羟基四氢萘基脲衍生物具有优异的VR1拮抗剂活性，可用于预防和治疗与VR1活性相关的疾病，特别是用于治疗尿失禁、急迫性尿失禁、过度活动膀胱、慢性疼痛、神经病性疼痛、术后疼痛、类风湿性关节炎疼痛、神经痛、神经病、疼痛、神经损伤、缺血、神经退行性疾病、中风、炎症性疾病、哮喘和COPD。
• ETHER DERIVATIVE
  申请人：Ajinomoto Co., Inc.

  公开号：EP1679296A1

  公开（公告）日：2006-07-12

  The present invention relates to an ether derivative represented by the formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description, and an ether derivative represented by the formula (III), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description; a pharmaceutical composition containing the ether derivative; and a package containing the pharmaceutical composition and a description of use thereof. A pharmaceutical composition of the present invention, which contains this compound of the present invention has a superior anti-inflammatory and analgesic activity and is useful as various pharmaceutical agents such as an anti-inflammatory agent, an analgesic, a therapeutic agent for inflammatory bowel disease, a therapeutic agent for pollakiuria and/or incontinentia, a therapeutic agent for asthma and the like.

  本发明涉及一种由式（I）表示的醚衍生物、其药学上可接受的盐、其水合物或其溶液 其中各符号如描述中所定义，以及由式（III）表示的醚衍生物、其药学上可接受的盐、其水合物或其溶物 其中各符号在说明中定义；含有醚衍生物的药物组合物；以及含有药物组合物及其使用说明的包装。含有本发明化合物的本发明药物组合物具有优异的抗炎和镇痛活性，可用作各种药物制剂，如抗炎剂、镇痛剂、炎症性肠病治疗剂、花粉尿症和/或失禁治疗剂、哮喘治疗剂等。